Literature DB >> 31100194

IL-6 Trans-signaling Controls Liver Regeneration After Partial Hepatectomy.

Nastaran Fazel Modares1, Robin Polz1, Fereshteh Haghighi1, Larissa Lamertz1, Kristina Behnke2, Yuan Zhuang2, Claus Kordes3, Dieter Häussinger3, Ursula R Sorg4, Klaus Pfeffer4, Doreen M Floss1, Jens M Moll1, Roland P Piekorz1, M Reza Ahmadian1, Philipp A Lang2, Jürgen Scheller1.   

Abstract

Interleukin-6 (IL-6) is critically involved in liver regeneration after partial hepatectomy (PHX). Previous reports suggest that IL-6 trans-signaling through the soluble IL-6/IL-6R complex is involved in this process. However, the long-term contribution of IL-6 trans-signaling for liver regeneration after PHX is unknown. PHX-induced generation of the soluble IL-6R by ADAM (a disintegrin and metallo) proteases enables IL-6 trans-signaling, in which IL-6 forms an agonistic complex with the soluble IL-6 receptor (sIL-6R) to activate all cells expressing the signal-transducing receptor chain glycoprotein 130 (gp130). In contrast, without activation of ADAM proteases, IL-6 in complex with membrane-bound IL-6R and gp130 activates classic signaling. Here, we describe the generation of IL-6 trans-signaling mice, which exhibit boosted IL-6 trans-signaling and abrogated classic signaling by genetic conversion of all membrane-bound IL-6R into sIL-6R proteins phenocopying hyperactivation of ADAM-mediated shedding of IL-6R as single substrate. Importantly, although IL-6R deficient mice were strongly affected by PHX, survival and regeneration of IL-6 trans-signaling mice was indistinguishable from control mice, demonstrating that IL-6 trans-signaling fully compensates for disabled classic signaling in liver regeneration after PHX. Moreover, we monitored the long-term consequences of global IL-6 signaling inhibition versus IL-6 trans-signaling selective blockade after PHX by IL-6 monoclonal antibodies and soluble glycoprotein 130 as fragment crystallizable fusion, respectively. Both global IL-6 blockade and selective inhibition of IL-6 trans-signaling results in a strong decrease of overall survival after PHX, accompanied by decreased signal transducer and activator of transcription 3 phosphorylation and proliferation of hepatocytes. Mechanistically, IL-6 trans-signaling induces hepatocyte growth factor production by hepatic stellate cells.
Conclusion: IL-6 trans-signaling, but not classic signaling, controls liver regeneration following PHX.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 31100194     DOI: 10.1002/hep.30774

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  Synthetic interleukin 22 (IL-22) signaling reveals biological activity of homodimeric IL-10 receptor 2 and functional cross-talk with the IL-6 receptor gp130.

Authors:  Sofie Mossner; Marcus Kuchner; Nastaran Fazel Modares; Birgit Knebel; Hadi Al-Hasani; Doreen M Floss; Jürgen Scheller
Journal:  J Biol Chem       Date:  2020-07-01       Impact factor: 5.157

2.  Myeloid peroxisome proliferator-activated receptor α deficiency accelerates liver regeneration via IL-6/STAT3 pathway after 2/3 partial hepatectomy in mice.

Authors:  Guomin Xie; Yanting Song; Na Li; Zhenzhen Zhang; Xia Wang; Ye Liu; Shiyu Jiao; Ming Wei; Baoqi Yu; Yan Wang; Hua Wang; Aijuan Qu
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

Review 3.  Liver regeneration biology: Implications for liver tumour therapies.

Authors:  Christopher Hadjittofi; Michael Feretis; Jack Martin; Simon Harper; Emmanuel Huguet
Journal:  World J Clin Oncol       Date:  2021-12-24

4.  Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.

Authors:  Xin Hou; Shi Yin; Ruixue Ren; Siqi Liu; Liang Yong; Yuxiao Liu; Yu Li; Ming-Hua Zheng; George Kunos; Bin Gao; Hua Wang
Journal:  Hepatology       Date:  2021-04-27       Impact factor: 17.298

Review 5.  New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology.

Authors:  Maria D Giraldez; David Carneros; Christoph Garbers; Stefan Rose-John; Matilde Bustos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-01       Impact factor: 46.802

Review 6.  Immunopathobiology and therapeutic targets related to cytokines in liver diseases.

Authors:  Yong He; Seonghwan Hwang; Yeni Ait Ahmed; Dechun Feng; Na Li; Marcelle Ribeiro; Fouad Lafdil; Tatiana Kisseleva; Gyongyi Szabo; Bin Gao
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

7.  Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6/STAT3 signalling.

Authors:  Seth A Domfeh; Patrick W Narkwa; Osbourne Quaye; Kwadwo A Kusi; Gordon A Awandare; Charles Ansah; Alimatu Salam; Mohamed Mutocheluh
Journal:  BMC Complement Med Ther       Date:  2021-06-02

8.  Efficiently Restored Thrombopoietin Production by Ashwell-Morell Receptor and IL-6R Induced Janus Kinase 2/Signal Transducer and Activator of Transcription Signaling Early After Partial Hepatectomy.

Authors:  Friedrich Reusswig; Nastaran Fazel Modares; Marius Brechtenkamp; Leonard Wienands; Irena Krüger; Kristina Behnke; Melissa M Lee-Sundlov; Diran Herebian; Jürgen Scheller; Karin M Hoffmeister; Dieter Häussinger; Margitta Elvers
Journal:  Hepatology       Date:  2021-06-04       Impact factor: 17.298

9.  Kupffer cell restoration after partial hepatectomy is mainly driven by local cell proliferation in IL-6-dependent autocrine and paracrine manners.

Authors:  Yeni Ait Ahmed; Yaojie Fu; Robim M Rodrigues; Yong He; Yukun Guan; Adrien Guillot; Ruixue Ren; Dechun Feng; Juan Hidalgo; Cynthia Ju; Fouad Lafdil; Bin Gao
Journal:  Cell Mol Immunol       Date:  2021-07-19       Impact factor: 22.096

10.  High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure.

Authors:  Chao Zhou; Ning Zhang; Ting-Ting He; Yao Wang; Li-Fu Wang; Yong-Qiang Sun; Jing Jing; Jing-Jing Zhang; Shuang-Nan Fu; Xuan Wang; Xiao-Xiao Liang; Xin Li; Man Gong; Jun Li
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.